Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | ATR | Q13535 | 10/20 | 0.47 |
| ▸ | PRKDC | P78527 | 3/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20899047 | 0.87 | LDHA (0.50) | IKBKBATRPRKDCLDHANPC1 | |
| SCHEMBL3461782 | 0.83 | IKBKB (0.48) | IKBKBATRPRKDCBAZ2BNPC1 | |
| SCHEMBL14525246 | 0.81 | ATR (0.65) | ATRPRKDCATM | |
| SCHEMBL22595056 | 0.80 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2ATM | |
| SCHEMBL3525387 | 0.75 | SMN1; SMN2 (0.48) | NPC1PDGFRBKDRFLT3RAB9A | |
| SCHEMBL11223967 | 0.74 | SMN1; SMN2 (0.51) | NPC1PDGFRBKDRFLT3RAB9A | |
| SCHEMBL25810607 | 0.74 | PTPN11 (0.35) | ATRPRKDCATM | |
| SCHEMBL10616051 | 0.72 | KDM4E (0.52) | ATRNPC1PDGFRBKDRFLT3 | |
| SCHEMBL4798197 | 0.71 | FTO (0.59) | LDHARAB9ASMN1; SMN2MAP2K3ADORA3 | |
| SCHEMBL6990771 | 0.71 | IKBKB (0.51) | IKBKBATRPRKDCLDHASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-11702411-B2 | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN1 | IKBKB 870/4885ATR 643/4885PRKDC 595/4885 |
| US-11702411-B2 | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN1 | IKBKB 870/4885ATR 643/4885PRKDC 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.